Neboglamine (CR 2249)

Best Price Available

Overview

Neboglamine, originally coded CR 2249 and given the international non-proprietary name nebostinel, is a glutamic acid derivative developed by Rotta Research Laboratorium in Monza, Italy, and later carried by Rottapharm. It was selected from a series of glutamate analogs as a positive modulator of the NMDA receptor complex, and its intended indications were memory disorders and later schizophrenia and cocaine dependence rather than general cognitive enhancement. It has never been approved anywhere and is not in active development. The material sold to consumers is the hydrochloride salt of a compound that has no published human data. The pharmacology is stereospecific, which is a useful marker of a real target. The S enantiomer, (S)-CR 2249, facilitated the ability of glycine to reverse kynurenate antagonism at strychnine-insensitive glycine receptors coupled to the NMDA receptor in rat hippocampal slices. It did not shift the potency of glycine but increased the efficacy of the glycine effect in a concentration-dependent way, and it increased [3H]MK-801 binding with positive cooperative interaction with glycine, which suggests it acts at a separate allosteric site rather than at the glycine site itself (PMID: 9294970). In a comparison of putative cognition enhancers, CR 2249 was potent in the kynurenate test while its enantiomer CR 2361 was inactive (PMID: 9336311), and the same enantiomeric selectivity appeared in slices of human neocortex removed during neurosurgery (PMID: 10381808). ChEMBL classifies the mechanism as positive allosteric modulation of the NMDA receptor (ChEMBL1255840). Behavioral work in rodents supports both a memory and an antipsychotic-like profile. CR 2249 improved memory retention after scopolamine in a step-through passive avoidance task in rats and after electroconvulsive shock in a step-down task in mice, and it improved performance in animals with no induced cognitive deficit. The effect appeared only when the compound was given before training, not after training or before the retention trial, and microdialysis showed increased noradrenaline release in the hippocampus of freely moving rats (PMID: 9004193). In a later company study, neboglamine increased Fos-like immunoreactivity in rat prefrontal cortex, nucleus accumbens and lateral septal nucleus in a pattern resembling D-serine, without the striatal activation seen with haloperidol, and it inhibited phencyclidine-induced hyperlocomotion and rearing without changing basal locomotor activity (PMID: 20045056). The human record is the problem. Commercial pipeline databases list phase 2 work in schizophrenia and cocaine dependence starting in 2010, and ChEMBL records a maximum phase of 2, but no trial result has been published in the peer-reviewed literature and searches of ClinicalTrials.gov and the EU Clinical Trials Register return no records under neboglamine, nebostinel or CR 2249. That means there is no published human pharmacokinetic profile, no published safety dataset and no efficacy result of any kind. Neboglamine is not approved in any country, is not a controlled substance in the United States and has no established human dose or safety threshold. It is a research-use-only compound whose entire published evidence base is rodent and ex vivo tissue work from the 1990s and 2010.

Potential Research Fields

Contraindications

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

$69.99

—

1

1

capsule

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Neboglamine (CR 2249).

Tracking since Sep 7, 2026 · 1 data point

Best Price